A First-in-human Phase 1 Study of BXQ-350, a First-in-class Sphingolipid Metabolism Regulator, in Patients with Advanced/recurrent Solid Tumors or High-Grade Gliomas
Clinical Cancer Research（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined